Acid acetilsalycilic action mechanism on haemostasis processes

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Review is devoted to the mechanisms of antihaemostatic action of acetilsalycilic acid (aspirin). It is the most widely used antiplatelet agent, that usually used in dosage of 50 mg to 325 mg daily to achive antithrombotic effect. Aspirinys mechanism of action is its ability to irreversible inactivation of cyclo-oxigenase for the lifespan of the platelet. Other mechanisms of platele inhibition by ASA have been proposed. The inhibition of prostaglandin synthesis is responsible for anti-inflammatory effect of ASA but it also results in the alteration of normal protective prostaglandin functions with potentially serious consequences, including gastric ulcers and impaired platelet function with haemorrhagic complications. Some of patients appear to be resistant to the antihaemostatic effect of aspirin. There are several biochemical factors that may contribute to this individual resistance.

About the authors

A. S. Shitikova

Russian research institute of haematology and transfusiology

Author for correspondence.
Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg, 193024

References

  1. Аверков О. В., Явелов И. С. Основные направления антитромботического лечения ишемической болезни сердца // Кардиология. 1997. Т. 37. № 7. С. 89-95.
  2. Александрова Н.А., Брагина Г. И., Кабаева Е. В., Таратута Г. В. Аспирин в комплексной медицинской профилактике больных ИБС с гиперхолестеринемией // Тромбозы, геморрагии, ДВС-синдром. Проблемы лечения /V Всероссийская конференция. 22-24.03. М., 2000. С. 21-22.
  3. Балуда В.И., Деянов И.И., Балуда М.В и др. Профилактика тромбозов. Саратов: Изд-во Саратовского ун-та, 1992.
  4. Баркаган 3. С. Очерки антитромботической фармакопрофилактики и терапии. М.: Ньюди-амед, 2000.
  5. Белязо О.Е., Шитикова А.С., Каргин В.Д.,Тарковская Л.Р. Нарушения системы гемостаза при артериальных и венозных тромбозах различной локализации и ее изменения при применении малых и больших доз аспирина // Тромбоз, гемостаз и реология. 2001. Т. 1. № 1. С. 34-40.
  6. Габриелян Э. С., Акопов С. Э. Клетки крови и кровообращение. Ереван: Айастан, 1985.
  7. Ленковски Ф., Нейринк Л. Г, Глезер С. В. Применение ацетилсалициловой кислоты при ИБС // Тер. архив. 1996. Т. 68. № 8. С. 79-83.
  8. Максимова М.Ю., Танашян М. М., Суслина З.А., Ионова В. Г Система вазоактивных простаноидов и тромбоцитарно-сосудистый гемостаз у больных с лакунарным инсультом // Тромбозы, геморрагии, ДВС-синдром. Проблемы лечения / V Всероссийская конференция. 22-24.03. М., 2000. С. 119-120.
  9. Митерев Ю. Г, Кубанцева И. В., Воронина Л. Н. и др. Применение ацетилсалициловой кислоты и препаратов декстрана в лечении ишемической болезни сердца // Сов. мед. 1985. № 9. С. 74-78.
  10. Окороков А. Н. Лечение болезней внутренних органов. Т. 3. Книга 1. Минск: Высшая школа, 1997.
  11. Олъбинская Л. И., Гофман А. М. Лечение и профилактика тромбозов. М.: ВАГРИУС, 2000.
  12. Попова Л. В., Носова Т.Н., Бокарев И. Н. Запись агрегатограммы - метод контроля антиагрегантной терапиии аспирином? // Тромбозы, геморрагии, ДВС-синдром. Проблемы лечения / V Всероссийская конференция. 22-24.03. М., 2000. С. 13 3-13 5.
  13. Сидоренко Б. А., Преображенский Д. В. АНТИ- тромботические препараты, применяемые при лечении сердечно-сосудистых заболеваний // Кардиология. 1996. Т. 36. № 1. С. 68-83; № 5. С. 74-85; № 7. С. 66-76.
  14. Шитикова А. С. Тромбоцитарный гемостаз. СПб.: Изд-во СПб ГМУ, 2000.
  15. Шитикова А. С. Изменение формы тромбоцитов как показатель их внутрисосудистой активации // Клинико-лабораторная диагностика предтромботических состояний / НИИ гематологии и переливания крови. 1991. С. 38-52.
  16. Akopov S., Grigorian G., Gabrielian E. Dose dependent aspirin hydrolysis and platelet aggregation in patients with atherosclerosis // J. Clin. Pharmacol. 1992. Vol. 32. P. 133-135.
  17. Altman R., Scazziota A., Rouvier J., Gonzalez C. Effect of sodium arachidonate on thrombin generation through platelet activation - inhibitory effect of aspirin // Thromb. Haemost. 2000. Vol. 84. P. 1109-1112.
  18. Antiplatelet Trialistsy Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I // Brit. Med. J. 1994. Vol. 308. P. 81-106.
  19. Awtry E.H., Loscalzo J. Aspirin // Circulation. 2000. Vol. 101. P. 1206-1218.
  20. Bennett J. S., Mousa S. Platelet function inhibitors in the year 2000 // Thromb. Haemost. 2001. Vol. 85. P. 395-400.
  21. Bousser M. G. Antithrombotic strategy in stroke//Thromb. Haemost. 2001. Vol. 86. P. 1-7.
  22. Breddin H. K. Antiplatelet agents in cardiovascular and cerebrovascular diseases // Clin. Appl. Thromb. /Hemost. 1998. Vol. 4. P. 87-95.
  23. Cairns J.A., Gent M., Singer J. et al. Aspirin, sulfinpyrazone, or both in unstable angina // N.Engl. J. Med. 1985. Vol. 313. P. 1369-1375.
  24. Catella-Lawson F., FitzGerald G. A. Long term aspirin in the prevention of cardiovascular disorders // Drug Safety. 1995. Vol. 13. P. 69-75.
  25. Clarke R.J., Mayo G., Price P, FitzGerald G.A. Suppresion of thromboxane A2 but not of systhemic prostacyclin by controlled-release aspirin // N.Engl. J. Med. 1991. Vol. 325. P. 1137-1141.
  26. Early Treatment of Diabetic Retinopathy Study (ETDRS) report. ETDRS investigators. Aspirin effect on mortality and morbility in patients with diabetes mellitus // JAMA. 1992. Vol. 268. P. 1292-1300.
  27. FitzGerald G.A. Beyond aspirin: EPIC opens the door//Vessels. 1995. Vol. 1. P. 3-13.
  28. FitzGerald G. A., Smith В., Pedersen А. К., Brash A. R. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation // N. Engl. J. Med. 1984. Vol. 310. P. 1065-1074.
  29. Gaziano J. M., Skerrett P J., Buring J. E. Aspirin in the treatment and prevention of cardiovascular diseases // Haemostasis. 2000. Vol. 30. Suppl. 3. P. 1-13.
  30. Grotemeyer К. H., Scharafinski H. W., Hussted I. W. Two-year follow-up of aspirin responder and aspirin non-responder // Thromb. Res. 1993. Vol. 71. P. 397-403.
  31. Hansson L., Zanchetty A., Carruthers S. G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension // Lancet. 1998. Vol. 351. P. 1755-1762.
  32. Helgason C.M., Bolin K.M., Hoff J. A. et al. Development of aspirin resistance in person with previous ischemic stroke // Stroke. 1994. Vol. 25. P. 2331-2336.
  33. Hoffman M., Mouroe D. M. A cell-based model of haemostasis // Thromb. Haemost. 2001. Vol. 85. P. 958-963.
  34. Husain S., Andrews N. P, Mulcahy D. et al. Aspirin improves endothelial disfunction in atherosclerosis // Circulation. 1998. Vol. 97. P. 716-720.
  35. Ingerman-Wojenski C., Smith B., Silver M.J. Evaluation of electrical aggregometry: comparison with optical aggregometry, secretion of ATP, and accumulation of radiolabeled platelets // J.Lab. Clin. Med. 1983. Vol. 101. P. 44-52.
  36. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group // Lancet. 1988. Vol. 2. P. 349-360.
  37. Ishikava K, Kanamasa K., Ogawa I. et al. Aspirin 50 mg per day with either dipiridamol or ticlopidin significantly reduced recurrent myocardial infarction (abstract) // Circulation. 1991. Vol. 84. Suppl. II. P. 367.
  38. Lewis H.D., Davis J. W., Archibald D.J. et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina // N.Engl. J. Med. 1983. Vol. 3 09. P. 396-403.
  39. MacloufJ., Folco G., Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and tran-scellular biosynthesis in vascular disease // Thromb. Haemost. 1998. Vol. 79. P. 691-705.
  40. Maeda N. Y., Lopes A. A. B., Bydlowski S. P. Cytoskeletal organisation and incoporation of b3 integrin in thrombin-stimulated platelets: effect of acetylsalicylic acid // Clin. Appl. Thromb. /Hemost. 1999. Vol. 5. P. 16-20.
  41. Manson J. E., Stampfer M.J., Colditz G.A. et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women // JAMA. 1991. Vol. 266. P. 521-527.
  42. McGaham M. C. Copper and aspirin treatment increase the antioxidant activity of plasma // Agents Actions. 1990. Vol. 31. P. 59-64.
  43. The Medical Research Council’s General Practice Research Framework Thrombosis Prevention Trial // Lancet. 1998. Vol. 351. P. 233-241.
  44. Michelson A. D. Laboratory markers of platelet activation // Eds. Colman R. W., Hirsh J., Marder V. J. et al. Hemostasis and thrombosis. Philadelphia, Baltimore, New York et al.: Lippincott Williams and Wilkins, 2001. P. 1102-1111.
  45. Mueller M. R., Salat A., Stangl P. et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty // Thromb. Haemost. 1997. Vol. 78. P. 1003-1007.
  46. Musial J., Undas A., Undas R. et al. Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and bordeline-high cholesterol levels // Thromb. Haemost. 2001. Vol. 85. P. 221-225.
  47. Nair G. V., Davis C.J., McKenzie M.E. et al. Aspirin in patients with coronary artery disease: is it simply irresistible? // J. Thromb. Thrombolysis. 2001. Vol. 11. P. 117-126.
  48. Patrono C., Patrignani P., Rocca B., Landolfi R. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development // Thromb. Haemost. 1995. Vol. 74. P. 396-400.
  49. Pedersen A.K., FitzGerald G. A. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase // N.Engl. J.Med. 1984. Vol. 311. P. 1206-1211.
  50. Peto R., Gray R., Collins R. et al. Randomised trial of prophylactic daily aspirin in Britishmale doctors // Brit. J. Med. 1988. Vol. 296. P. 313-316.
  51. Quick A. J. Salicylates and bleeding: the aspirin tolerance test // Amer. J. Med. Sci. 1967. Vol. 252. P. 265-269.
  52. Rao A. K. Acquired qualitative platelet defects // Eds. Colman R. W., Hirsh J., Marder V. J. et al. Hemostasis and thrombosis. Philadelphia, Baltimore, New York et al.: Lippincott Williams and Wilkins, 2001. P. 905-919.
  53. Ratnatunga C.P., Edmondson S.F, Rees G.M., Kovacs /. B. Hagh-dose aspirin inhibits shear-indused platelet reaction involving thrombin generation // Circulation. 1992. Vol. 85. P. 1077-1082.
  54. Roth G.J., Calverly D. C. Aspirin, platelets, and thrombosis: theory and practice // Blood. 1994. Vol. 83. P. 885-898.
  55. Roth G.J., Majerus P.W.The mechanism of effect of aspirin on human platelets // J. Clin. Invest. 1975. Vol. 56. P. 624-632.
  56. Sakariassen K. S., Cadroy Y. Impact of shear, collagen fibrils and tissue factor on anticoagulant and antiplatelet agents // 16-th International Congress on Thrombosis 5-8.05 / Porto-Portugal. 2000. P. 14-17.
  57. Santos M. T., Moscardo A., Valles J. et al. Partipation of tyrosine phosphorilation in cytoskeletal reorganization, αIIbβ3 integrin receptor activation, and aspirin-insesivity mechanisms of thrombin-stimulated platelets // Circulation. 2000. Vol. 102. P. 1924-1930.
  58. Schneider D.J., Baumann P.Q., Holmes M.B.et al. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin // Thromb. Haemost. 2001. Vol. 85. P. 309-313.
  59. Steer K.A., Wallace T.M., Bolton C.H., Hartog M. Aspirin protect low density lipoprotein from oxidative modification // Heart. 1997. Vol. 77. P. 333-337.
  60. Steering Committee of the Physiciansy Health Study Research Group. Final report on the aspirin component of the ongoing Physiciansy Health Study // N.Engl. J. Med. 1989. Vol. 321. P. 129-135.
  61. Stenberg P., Sundqvist S. B. Drug induced bleeding disorders // Ed. H.Renck. Bleeding and thrombosis disorders in surgical patients / E. Norwalk: Appletion and Lange, 1988. P. 37-44.
  62. Theroux P, Ouimet H., McCans J. et al. Aspirin, heparin or both to treat acute unstable angina // N.Engl. J.Med. 1988. Vol. 319. P. 1105-1111.
  63. Van de Graaff E., Steinhubl S. R. Variable interindividual responses to antiplatelet the rapies - do they exist, can we measure them, and are they clinically relevant? // Heart Drug. 2001. Vol. 1. P. 35-43.
  64. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs // Nature. 1971. Vol. 231. P. 232-235.
  65. Wallentin L. C. Research group on instability in coronary artery disease in Southeast Sweden // J. Amer. Coll. Cardiol. 1991. Vol. 18. P. 1587-1593.
  66. Waterhous D. Aspirin, NSAIDs and risk reduction of colorectal cancer // Arch. Int. Med. 1994. Vol. 154. P. 366-368.
  67. Webber C., Erl W., Pietsch A. et al. Aspirin inhibits nuclear factor-кВ mobilization and monocyte adhesion in stimulated human endothelial cells // Circulation. 1995. Vol. 91. P. 1914-1917.
  68. Weiss H.J., Aledort L. M. Impaired platelet-connective-tissue reaction in man after aspirin ingestion // Lancet. 1967. Vol. 2. P. 495-497.
  69. Willard J. E., Lange R. A., Hillis L. D. The use of aspirin in ischemic heart disease // N.Engl. J.Med. 1992. Vol. 327. P. 175.
  70. Wu K. K. Aspirin and salicylate. An old remedy with newtwist // Circulation. 2000. Vol. 102. P. 2022-2023.
  71. Zimmerman N., Klenzle P, Weber A. et al. Platelet aspirin resistance is associated with an increased platelet content of cyclooxygenase-2 // Circulation. 1999. Vol. 100. Suppl. P. 1-327.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.